Hi everyone
My name is Eleanor and I work in the policy team at Breast Cancer Now.
We’re really interested to hear from anyone who has received the treatment capivasertib in combination with fulvestrant (also known as Truqap with Faslodex). This combination is used to treat hormone receptor-positive, HER2-negative secondary breast cancer after endocrine treatment. You may have received it as part of a clinical trial.
The combination is being assessed to see if it should be made available through the NHS and we would love to hear your views.
If you can help, please get in touch via policy@breastcancernow.org
Thanks so much